Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Early research (Phase 1)Looking for participantsNCT05013216
What this trial is testing

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Who this might be right for
High Risk CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 37
Not applicableTemporarily Not AvailableNCT07614048
What this trial is testing

Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS

Who this might be right for
PDAC - Pancreatic Ductal AdenocarcinomaColorectal Cancer
Providence Health & Services
Early research (Phase 1)Active Not RecruitingNCT05462717
What this trial is testing

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma+1 more
Revolution Medicines, Inc. 222
Early research (Phase 1)Active Not RecruitingNCT04117087
What this trial is testing

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Who this might be right for
Colorectal CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Early research (Phase 1)Looking for participantsNCT06835569
What this trial is testing

Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Who this might be right for
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc. 448
Early research (Phase 1)Looking for participantsNCT06411691
What this trial is testing

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Who this might be right for
Colorectal CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 54
Early research (Phase 1)Looking for participantsNCT07458347
What this trial is testing

Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Who this might be right for
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc. 145
Early research (Phase 1)Not Yet RecruitingNCT07624214
What this trial is testing

Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. 198
Early research (Phase 1)Looking for participantsNCT07349537
What this trial is testing

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Adenocarcinoma+7 more
Revolution Medicines, Inc. 574
Early research (Phase 1)Looking for participantsNCT06917079
What this trial is testing

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Who this might be right for
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 665
Early research (Phase 1)Looking for participantsNCT06040541
What this trial is testing

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Revolution Medicines, Inc. 604
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07640295
What this trial is testing

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Who this might be right for
Metastatic Pancreatic Ductal Adenocarcinoma
Jacobio Pharmaceuticals Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT07629960
What this trial is testing

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more
Blueprint Medicines Corporation 265